128 related articles for article (PubMed ID: 20008635)
21. KRAS-mutation positive, metastatic tonsil carcinoma with cancer stem-like cell features and long-term response to gefitinib: a case report and review of the literature.
Gottschling S; Penzel R; Pelz T; Herpel E; Schnabel PA; Dyckhoff G; Thomas M; Kuhnt T
J Clin Oncol; 2011 Jul; 29(21):e616-9. PubMed ID: 21555681
[No Abstract] [Full Text] [Related]
22. Pulmonary pleomorphic carcinoma: a clinicopathological study including EGFR mutation analysis.
Kaira K; Horie Y; Ayabe E; Murakami H; Takahashi T; Tsuya A; Nakamura Y; Naito T; Endo M; Kondo H; Nakajima T; Yamamoto N
J Thorac Oncol; 2010 Apr; 5(4):460-5. PubMed ID: 20107421
[TBL] [Abstract][Full Text] [Related]
23. [Importance of pathology research on lung adenocarcinoma].
Zhu XZ
Zhonghua Bing Li Xue Za Zhi; 2012 Oct; 41(10):649-51. PubMed ID: 23302303
[No Abstract] [Full Text] [Related]
24. EGFR mutations in squamous cell lung cancer in never-smokers.
Baik CS; Pritchard CC; Eaton KD; Chow LQ
J Thorac Oncol; 2013 Jan; 8(1):e6-7. PubMed ID: 23242446
[No Abstract] [Full Text] [Related]
25. Epithelial-mesenchymal transition in EGFR-TKI acquired resistant lung adenocarcinoma.
Uramoto H; Iwata T; Onitsuka T; Shimokawa H; Hanagiri T; Oyama T
Anticancer Res; 2010 Jul; 30(7):2513-7. PubMed ID: 20682976
[TBL] [Abstract][Full Text] [Related]
26. EGFR exon 19 insertions show good response to gefitinib, but short time to progression in Japanese patients.
Park J; Kondo C; Shimizu J; Horio Y; Yoshida K; Hida T
J Thorac Oncol; 2014 Feb; 9(2):e10-1. PubMed ID: 24419426
[No Abstract] [Full Text] [Related]
27. Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer.
Sette G; Salvati V; Mottolese M; Visca P; Gallo E; Fecchi K; Pilozzi E; Duranti E; Policicchio E; Tartaglia M; Milella M; De Maria R; Eramo A
Cell Death Dis; 2015 Aug; 6(8):e1850. PubMed ID: 26247735
[TBL] [Abstract][Full Text] [Related]
28. Two rare exon 21 EGFR mutations in patients treated with gefitinib.
Mompradé E; Arriola E; Martínez-Avilés L
J Thorac Oncol; 2013 Apr; 8(4):e36-7. PubMed ID: 23486275
[No Abstract] [Full Text] [Related]
29. Phase II study of erlotinib in elderly patients with non-small cell lung cancer harboring epidermal growth factor receptor mutations.
Inoue Y; Inui N; Asada K; Karayama M; Matsuda H; Yokomura K; Koshimizu N; Imokawa S; Yamada T; Shirai T; Kasamatsu N; Suda T
Cancer Chemother Pharmacol; 2015 Jul; 76(1):155-61. PubMed ID: 26003540
[TBL] [Abstract][Full Text] [Related]
30. Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma.
Kosaka T; Yatabe Y; Onozato R; Kuwano H; Mitsudomi T
J Thorac Oncol; 2009 Jan; 4(1):22-9. PubMed ID: 19096302
[TBL] [Abstract][Full Text] [Related]
31. Good response to gefitinib in lung adenocarcinoma of complex epidermal growth factor receptor (EGFR) mutations with the classical mutation pattern.
Wu SG; Chang YL; Hsu YC; Wu JY; Yang CH; Yu CJ; Tsai MF; Shih JY; Yang PC
Oncologist; 2008 Dec; 13(12):1276-84. PubMed ID: 19060236
[TBL] [Abstract][Full Text] [Related]
32. Complete pathologic response in lung tumors in two patients with metastatic non-small cell lung cancer treated with erlotinib.
Weber B; Sorensen BS; Knap MM; Madsen HH; Nexo E; Meldgaard P
J Thorac Oncol; 2011 Nov; 6(11):1946-9. PubMed ID: 22005472
[TBL] [Abstract][Full Text] [Related]
33. How sensitive are epidermal growth factor receptor-tyrosine kinase inhibitors for squamous cell carcinoma of the lung harboring EGFR gene-sensitive mutations?
Hata A; Katakami N; Yoshioka H; Kunimasa K; Fujita S; Kaji R; Notohara K; Imai Y; Tachikawa R; Tomii K; Korogi Y; Iwasaku M; Nishiyama A; Ishida T
J Thorac Oncol; 2013 Jan; 8(1):89-95. PubMed ID: 23242440
[TBL] [Abstract][Full Text] [Related]
34. A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705.
Yoshioka H; Hotta K; Kiura K; Takigawa N; Hayashi H; Harita S; Kuyama S; Segawa Y; Kamei H; Umemura S; Bessho A; Tabata M; Tanimoto M;
J Thorac Oncol; 2010 Jan; 5(1):99-104. PubMed ID: 19898258
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib.
Katayama T; Shimizu J; Suda K; Onozato R; Fukui T; Ito S; Hatooka S; Sueda T; Hida T; Yatabe Y; Mitsudomi T
J Thorac Oncol; 2009 Nov; 4(11):1415-9. PubMed ID: 19692934
[TBL] [Abstract][Full Text] [Related]
36. PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients.
Endoh H; Yatabe Y; Kosaka T; Kuwano H; Mitsudomi T
J Thorac Oncol; 2006 Sep; 1(7):629-34. PubMed ID: 17409929
[TBL] [Abstract][Full Text] [Related]
37. Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutations.
De Pas T; Toffalorio F; Manzotti M; Fumagalli C; Spitaleri G; Catania C; Delmonte A; Giovannini M; Spaggiari L; de Braud F; Barberis M
J Thorac Oncol; 2011 Nov; 6(11):1895-901. PubMed ID: 21841502
[TBL] [Abstract][Full Text] [Related]
38. Point: should epidermal growth factor receptor mutations be routinely tested for in patients with lung cancer? Yes.
Sterman DH
Chest; 2013 Mar; 143(3):597-600. PubMed ID: 23460149
[No Abstract] [Full Text] [Related]
39. Lung carcinomas with EGFR exon 19 insertions are sensitive to gefitinib treatment.
Iyevleva AG; Mitiushkina NV; Karaseva NA; Orlov SV; Volodina LN; Kulikova YE; Lozhkina AM; Ivantsov AO; Tiurin VI; Togo AV; Imyanitov EN
J Thorac Oncol; 2014 Apr; 9(4):e31-3. PubMed ID: 24736087
[No Abstract] [Full Text] [Related]
40. Epidermal growth factor receptor exon 19 deletions predict complete regression of multiple intracranial metastases in two cases of non-small cell lung cancer treated with erlotinib.
Benedetti G; Latini L; Galetta D; Colucci G; Crinò L
J Thorac Oncol; 2009 Jul; 4(7):936-7. PubMed ID: 19550250
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]